title: Topical Cidofovir for Recalcitrant Verrucae in Individuals with Severe Combined Immunodeficiency After Hematopoietic Stem Cell Transplantation.
abstract: Verrucae vulgaris in patients with severe combined immunodeficiency (SCID) after hematopoietic stem cell transplantation (HCST) can be challenging to manage. We describe two brothers with X-linked SCID who had severe, persistent verrucae that did not respond to traditional topical therapies, including liquid nitrogen, imiquimod, salicylic acid, sinecatechins, 40% urea, and 5-fluorourcil. Both brothers had full response to topical 3% cidofovir, which should be considered in recalcitrant warts in individuals with SCID after HSCT.
authors.affiliation: Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
authors.forename: Sarah E
authors.initials: SE
authors.lastname: Henrickson
authors.affiliation: Section of Pediatric Dermatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
authors.forename: James R
authors.initials: JR
authors.lastname: Treat
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D002648:Child; D000077404:Cidofovir; D003596:Cytosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D008297:Male; D063065:Organophosphonates / Q000627:therapeutic use*; D016511:Severe Combined Immunodeficiency / Q000209:etiology*; D016896:Treatment Outcome; D014860:Warts / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000998:Antiviral Agents; D063065:Organophosphonates; D003596:Cytosine; D000077404:Cidofovir